Clinical trial
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With…
NCT00206167 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00206167 |
|---|---|
| Title | A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD |
| Official title | A 12-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy and Safety Study of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid Compared to Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Obstructive Pulmonary Disease |
| Intervention type | Drug |
| Interventions | Budesonide/formoterol pMDI, Formoterol Turbuhaler |
| Enrollment | 1,600 |
| Start date | Apr 1, 2005 |
| Completion | Sep 1, 2007 |
| First posted | Sep 21, 2005 |
| Last update posted | Mar 27, 2009 |
| Countries | Bulgaria, Denmark, Germany, Greece, Hungary, Iceland, Mexico, Romania, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: